Effects of dexmedetomidine as an adjuvant in ultrasound-guided transversus abdominis plane block on propofol target-controlled infusion

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-17011609

Enrollment

Unknown

Registered

2017-06-09

Start date

2017-07-01

Completion date

Unknown

Last updated

2017-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

laparoscopic cholecystectomy

Interventions

Control group:TAP block on each side using 20 ml of ropivacaine 0.3%

Dex group:taP block on each side with 20 ml of ropivacaine 0.3% including 0.5 µg/kg dexmedetomidine

Eligibility

Sex/Gender

Female

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: ASA grade I-II female patients 18-65 years old, scheduled for laparoscopic cholecystectomy under propofol general anesthesia.

Exclusion criteria

Exclusion criteria: Patients with a history of allergy to local anesthetics, severe cardiovascular disease,cerebrovascular disease, peripheral neuropathy, hepatic or renal disorders, psychiatric disease, severe respiratory disease,and BMI=28 kg/m2 will be excluded.

Design outcomes

Primary

Measure	Time frame
dose of propofol during surgery;loss of consciousness;laryngeal mask insertion;	—

Secondary

Measure	Time frame
awaken time;extubation time;Steward score;postoperative nausea and vomiting;VAS score;dose of remifentanyl during surgery;	—

Countries

China

Contacts

Public ContactBoxiang Du

The Second Affiliated Hospital of Nantong University

boxiang_du@aliyun.com+86 0513 85061315

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026